How the main treatments are combined and sequenced
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
Merkel cell carcinoma (MCC) is treated with three main tools — surgery, radiation, and immunotherapy — used in different combinations depending on the stage. Because MCC returns and spreads more readily than basal or squamous cell cancers, treatment tends to be more intensive than patients expect for a skin cancer, and it usually involves several specialists.
This guide explains what each treatment does, how they are sequenced, and the questions that help you understand your own plan.
MCC care is usually coordinated across several specialties, ideally reviewed together at a tumor board:
The skin tumor is removed with a margin of normal-looking tissue around it (wide local excision), or by Mohs surgery on the face, where tissue conservation matters. At the same operation, a sentinel lymph node biopsy is usually done to check whether cancer has reached the draining nodes.
MCC is highly radiosensitive, and local recurrence is common. Radiation to the tumor bed is frequently recommended, especially for larger tumors, close or positive margins, lymphovascular invasion, or immunosuppression. If a sentinel node is positive, radiation and/or surgery is directed at the lymph node basin. Small, low-risk tumors removed with clear margins in people with intact immune systems are sometimes observed without radiation.
When surgery would be disfiguring, when a person is not well enough for an operation, or when the tumor is unresectable, definitive radiation can control MCC effectively on its own. It is also used to relieve symptoms from tumors that are causing pain or pressure.
For MCC that has spread to distant sites, or that has recurred and cannot be controlled with surgery and radiation, immune checkpoint inhibitors — avelumab, pembrolizumab, or nivolumab — are the standard first choice. Responses are often rapid and, in many patients, long-lasting. See advanced or metastatic MCC and checkpoint immunotherapy.
Platinum-based chemotherapy shrinks MCC in the short term but the benefit usually fades within months. It has largely been replaced by immunotherapy and is now reserved for people who cannot receive checkpoint inhibitors or whose disease has progressed through them.
Because MCC is rare and the field is moving quickly, trials — of immunotherapy before surgery, new immune combinations, and cellular therapies — are a mainstream option worth asking about at every stage, not only after other treatments fail.
MCC can progress in weeks, so treatment tends to start promptly and follow a planned order — typically surgery, then radiation a few weeks later once healing allows, with imaging and lymph node results guiding whether systemic therapy is added. Delays between steps are kept as short as safely possible. If you are facing a long wait for any part of the plan, it is reasonable to ask whether it can be expedited or whether another center can see you sooner.
For most people, MCC treatment is surgery to remove the tumor and sample the lymph nodes, followed by radiation to reduce the high risk of local recurrence. Immunotherapy is the standard for disease that has spread, and clinical trials run alongside all of it. The plan is individualized and moves quickly, which is exactly why a coordinated, experienced team makes a difference.
After active treatment, close follow-up and recurrence monitoring becomes the priority.
Disclaimer: Educational only. Not a substitute for professional medical advice. Always consult your dermatologist or oncologist about your personal diagnosis and treatment plan.
Chat with our AI guide for personalized information about Merkel cell carcinoma
Chat with the Navigator